Frontiergate Biopharm

Frontiergate Biopharm is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to discovering and developing novel small molecule drugs for cancer and autoimmune diseases. The company focuses on 'undruggable' targets within the RAS/MAPK signaling pathway and DNA damage response (DDR) pathways. Its lead program, FB849, is a highly selective KRAS G12C inhibitor currently in clinical development for solid tumors. Another key asset, FB753, is an HPK1 inhibitor targeting immuno-oncology indications. Founded by industry veteran Dr. Shuhui Chen, the company utilizes advanced medicinal chemistry and structural biology to address significant unmet medical needs. Frontiergate is supported by a strong syndicate of investors, including 6 Dimensions Capital and Sequoia China.